Related Experiment Video
Updated: Jun 29, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
Moderate mitral regurgitation in patients undergoing CABG--the MoMIC trial
Per Wierup1, Henrik Egeblad, Sten Lyager Nielsen
1Department of Cardiothoracic Surgery, Aarhus University Hospital, Skejby, Aarhus, Denmark. pwi@sks.aaa.dk
Insights
For patients undergoing coronary artery bypass grafting (CABG), the Moderate Mitral Regurgitation In Patients Undergoing CABG (MoMIC) trial investigates if correcting moderate ischemic mitral regurgitation (IMR) improves survival. Results will guide treatment decisions for this common condition.
Area of Science:
- Cardiology
- Cardiac Surgery
- Clinical Trials
Background:
- Moderate ischemic mitral regurgitation (IMR) is linked to poor long-term survival and heart failure hospitalizations.
- Current practice often omits mitral valve repair in CABG patients with moderate IMR.
- Lack of robust data necessitates a large-scale trial to inform clinical decision-making.
Purpose of the Study:
- To determine if mitral valve correction alongside CABG improves outcomes in patients with moderate IMR.
- To provide evidence-based guidance for managing moderate IMR during CABG surgery.
Main Methods:
- The Moderate Mitral Regurgitation In Patients Undergoing CABG (MoMIC) trial is an international, multi-center study.
- 550 patients with moderate IMR undergoing CABG will be randomized.
- Comparison of CABG alone versus CABG plus mitral valve correction.
- Primary endpoint: composite of mortality and heart failure rehospitalization at five years.
Main Results:
- Patient enrollment and randomization commenced in February 2008.
- The study is designed to provide definitive data on the efficacy of mitral valve correction in this population.
Conclusions:
- Findings will clarify whether mitral valve correction is a superior strategy for moderate IMR in CABG patients.
- If proven beneficial, the results are expected to influence clinical practice guidelines.
Background:
The presence of mild to moderate ischemic mitral regurgitation (IMR) marks a significantly reduced long-term survival and increased hospitalizations due to heart-failure. However, it is common practice in many institutions to refrain from repairing the mitral valve in these patients. There are no available conclusive data to support this practice, and thus there is a need for an adequately powered randomized trial.
Study Design:
The Moderate Mitral Regurgitation In Patients Undergoing CABG (MoMIC) trial is the first international multi-center, large-scale study to clarify whether moderate IMR in CABG patients should be corrected. A total of 550 CABG patients with moderate IMR are to be randomized to treatment of either CABG alone or CABG plus mitral valve correction. The primary end point is a composite end point of mortality and rehospitalization for heart failure at five years. The inclusion and randomization of patients started in February 2008.
Implication:
If correction of moderate IMR in CABG patients proves to be the superior strategy, most patients should be treated accordingly.
More Related Videos
07:42An Image Guided Transapical Mitral Valve Leaflet Puncture Model of Controlled Volume Overload from Mitral Regurgitation in the Rat
Published on: May 19, 2020
08:42Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
Related Concept Videos
Mitral Regurgitation III: Medical Management
Mitral Regurgitation I: Introduction
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Mitral Regurgitation IV: Nursing Management
Mitral Stenosis III: Medical Management
Mitral Stenosis II: Clinical features and Diagnostic Tests